

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5,023,252	6/11/91	Hseih
	5,034,506	7/23/91	Summerton et al.
	5,225,347	7/6/93	Goldberg et al.
	5,580,859	12/3/96	Felgner et al.
	5,719,262	2/17/98	Buchardt et al.
	5,766,855	6/16/98	Buchardt et al.
	5,834,279	11/10/98	Rubin et al.
	5,998,383	12/7/99	Wright et al.
	6,121,000	9/19/00	Wright et al.
	6,593,305	7/15/03	Wright et al.
	7,405,205	7/29/08	Wright et al.
	2006/0241070	10/26/2006	Wright

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)
	0 383 190	8/22/90	EP	
	94/21661	9/29/94	WO	
	95/02069	1/19/95	WO	
	98/00532	1/8/98	WO	
	98/05769	2/12/98	WO	

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
	99/02673	1/21/99	WO	
	00/47733	8/17/00	WO	
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)				
	Abaza et al., FASEB J., 15(4):A555, 2001 (Abstract only).			
	Agrawal et al., "Reconstitution of Signal Transduction from the Membrane to the Nucleus in a Baculovirus Expression System: Activation of Raf-1 Leads to Hypermodification of c-jun, and c-fos via Multiple Pathways," Oncogene 11(3):427-38, 1995.			
	Agrawal, "Antisense oligonucleotides: towards clinical trials" TIBTECH 14:376-387 1996.			
	Akhter et al., "Interactions of antisense DNA oligonucleotide analogs with phospholipid membranes (liposomes)" Nucleic Acids Res 19(20):5551-9, 1991.			
	Aksoy et al., "Combined interferon alpha with levamisole in patients with metastatic renal cell carcinoma" Int Urol Nephrol 33(3):457-9, 2001.			
	Amara et al., " Phorbol Ester Modulation of a Novel Cytoplasmic Protein Binding Activity at the 3'-Untranslated Region of Mammalian Ribonucleotide Reductase R2 mRNA and Role in Message Stability" J Biol Chem 269:6709-6715, 1994.			
	Amara et al., "Defining a novel cis-element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA. cis-trans-interactions and message stability" J Biol Chem 271(33):20126-31, 1996.			
	Amara et al., "Defining a novel cis element in the 3'-untranslated region of mammalian ribonucleotide reductase component R2 mRNA: role in transforming growth factor-beta 1 induced mRNA stabilization" Nucleic Acids Res 23(9):1461-7, 1995.			
	Atzpodi et al., "Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma" Cancer 95(5):1045-50, 2002.			
	Auer et al., "Bcl-2 antisense (Genasense™) induces apoptosis and potentiates activity of both cytotoxic chemotherapy and rituximab in primary CLL cells" Blood 98(11): 808a, 2001 (Abstract only).			
	Barker, R.H. Jr. et al., "Inhibition of Plasmodium falciparum malaria using antisense oligodeoxynucleotides" Proc Natl Acad Sci USA 93(1):514-518, 1996.			
	Bitonti et al., "Response of human colon and prostate tumor xenografts to (E)-2'-deoxy-2'-(fluoromethylene) cytidine, an inhibitor of ribonucleotide reductase" Anticancer Res 15(4): 1179-1182, 1995.			

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
(37 C.F.R. § 1.98(b))		IDS Filed	October 14, 2009

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Bitonti et al., "Regression of human breast tumor xenografts in response to (E)-2'-deoxy-2'-(fluoromethylene)cytidine, an inhibitor of ribonucleoside diphosphate reductase" Cancer Res 54(6):1485-1490, 1994.
	Bjorklund et al., "S-phase-specific expression of mammalian ribonucleotide reductase R1 and R2 subunit mRNAs" Biochemistry 29:5452-5458, 1990.
	Bjorklund et al., "Structure and promoter characterization of the gene encoding the large subunit (R1 protein) of mouse ribonucleotide reductase" Proc Natl Acad Sci USA 90:11322-11326, 1993.
	Blaesse, "Gene therapy for cancer" Scientific American 276(6):111-115, 1997.
	Bleumer et al. "Immunotherapy for renal cell carcinoma" Eur Urol 44(1):65-75, 2003.
	Blosmanis et al., "Sensitivity to melphalan as a function of transport activity and proliferative rate in BALB/c 3T3 fibroblasts" Cancer Res 47:1273-1277, 1987.
	Bradley et al., "Experimental metastasis in nude mice of NIH 3T3 cells containing various ras genes" Proc Natl Acad Sci USA 83:5277-5281, 1986.
	Branch, "A good antisense molecule is hard to find" Trends Biochem Sci 23(2):45-50, 1998.
	Calabretta et al., "Antisense strategies in the treatment of leukemias" Semin. Oncol. 23:78-87, 1996.
	Caras et al., "Cloned morse ribonucleotide reductase subunit M1 cDNA reveals amino acid sequence homology with Escherichia coli and Herpesvirus ribonucleotide reductase" Biol Chem., 260:7015-7022, 1985.
	Chadee et al., "Increased phosphorylation of histone H1 in mouse fibroblasts transformed with oncogenes or constitutively active mitogen-activated protein kinase kinase" J Biol Chem 270:20098-20105, 1995.
	Chakrabarti, et al., "Cloning and characterization of subunit genes of ribonucleotide reductase, a cell-cycle-regulated enzyme, from Plasmodium falciparum" Proc Natl Acad Sci USA 90:12020-12024, 1993.
	Chan et al., "Phosphorylation of ribonucleotide reductase R2 protein: in vivo and in vitro evidence of a role for p34cdc2 and CDK2 protein kinases" Biochemistry 32:12835-12840, 1993.
	Chaudhuri et al., "Cdn sequence of the small subunit of the hamster ribonucleotide reductase" Biochimica et Biophysica Acta 1117:117-121, 1992.
	Chen et al., "Defining a novel ribonucleotide reductase r1 mRNA cis element that binds to a unique cytoplasmic trans-acting protein" Nucleic Acids Res 22:4796-4797, 1994.
	Chen et al., "Mammalian ribonucleotide reductase R1 mRNA stability under normal and phorbol ester stimulating conditions: involvement of a cis-trans interaction at the 3' untranslated region" EMBO J 12:3977-3986, 1993.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Chitambar and Wereley, "Effect of hydroxyurea on cellular iron metabolism in human leukemic CCRF-CEM cells: changes in iron uptake and the regulation of transferrin receptor and ferritin gene expression following inhibition of DNA synthesis" Cancer Research 55:4361-4366, 1995.
	Chiu et al., "Inhibition of mammalian ribonucleotide reductase by cis-diamminedichloroplatinum(II)" Biochemistry and Cell Biology 70(12): 1332-1338, 1992.
	Cho-Chung, "Antisense DNAs as targeted therapeutics for cancer: no longer a dream" Curr Opin Investig Drugs 3(6):934-9, 2002.
	Choy et al, "Transient elevation of ribonucleotide reductase activity, M2 mRNA and M2 protein in BALB/c 3T3 fibroblasts in the presence of 12-O-tetradecanoylphorbol-13-acetate" Biochem Biophys Res Commun 162:1417-1424, 1989.
	Choy et al., "Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations" Cancer Res 48:2029-2035, 1988.
	Cole et al., "Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line" Science 258:1650-1654, 1992.
	Cory et al., "Structural aspects of N-hydroxy-N'-aminoguanidine derivatives as inhibitors of L1210 cell growth and ribonucleotide reductase activity" Adv Enzyme Regul 33:129-140, 1993.
	Crooke, "Progress in antisense therapeutics" Hematol Pathol 9(2):59-72, 1995.
	Davis et al., "Purification, characterization, and localization of subunit interaction area of recombinant mouse ribonucleotide reductase r1 subunit" J. Biol. Chem 269:23171-23176, 1994.
	Dutcher et al., "Preliminary report of a phase 1 study of intravenous (IV) CCI-779 given in combination with interferon- $\alpha$ (IFN) to patients with advanced renal cell carcinoma (RCC)" Proc Am Soc Clin Oncol 22:213, 2003 (Abstract 854).
	Duxbury et al, "RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine" Oncogene 23:1539-1548, 2004.
	Edwards et al., "Transcriptional regulation of two serum-induced RNAs in mouse fibroblasts: equivalence of one species to B2 repetitive elements" Mol Cell Biol 5:3280-3288, 1985.
	Eriksson et al., "Cell cycle-dependent regulation of mammalian ribonucleotide reductase. The S phase-correlated increase in subunit M2 is regulated by de novo protein synthesis" J Biol Chem 259:11695-11700, 1984.
	Fabianowska and Majewska, "2-Chloro-2'-deoxyadenosine (2CdA) biochemical aspects of antileukemic efficacy" Acta Pol Pharm 53(4):231-239, 1996.
	Fan et al., "Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with
EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	activated oncogenes to determine transformation and malignant potential" Proc Natl Acad Sci USA. 93(24):14036-40 1996.
	Fan et al., "A link between ferritin gene expression and ribonucleotide reductase R2 protein, as demonstrated by retroviral vector mediated stable expression of R2 cDNA" FEBS Lett 382:145-148, 1996.
	Fan et al., "The R1 component of mammalian ribonucleotide reductase has malignancy-suppressing activity as demonstrated by gene transfer experiments" Proc Natl Acad Sci 94:13181-13186, 1997.
	Funk et al., "A transcriptionally active DNA-binding site for human p53 protein complexes" Mol Cell Biol 12(6):2866-2871, 1992.
	Gandhi et al., "Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions" Blood 87(1):256-264, 1996.
	Gewirtz, "Oligodeoxynucleotide-based therapeutics for human leukemias" Stem Cells 11:96-103, 1993.
	Gewirtz et al., "Facilitating oligonucleotide delivery: helping antisense deliver on its promise" Proc Natl Acad Sci USA 93:3161-3163, 1996.
	Giacca et al., "Synergistic Antiviral Action of Ribonucleotide Reductase Inhibitors and 3'-azido-3'-deoxythymidine on HIV Type 1 Infection In Vitro" AIDS Res Hum Retroviruses 12(8):677-682, 1996.
	Gilboa, E., "Immunotherapy of cancer with genetically modified tumor vaccines" Semin Oncol 23(1):101-107, 1996.
	Goldberg et al., "Phase I trial of interferon alpha2b and liposome-encapsulated all-trans retinoic acid in the treatment of patients with advanced renal cell carcinoma" Cancer, 95(6):1220-7, 2002.
	Good and Nielsen, "Inhibition of translation and bacterial growth by peptide nucleic acid targeted to ribosomal RNA" Proc Natl Acad Sci USA. 95(5):2073-6, 1998.
	Gura, "Systems for identifying new drugs are often faulty" Science 278:1041-1042, 1997.
	Hanania et al., "Recent advances in the application of gene therapy to human disease" Am J Med 99:537-552, 1995.
	Hards and Wright, "N-carbamoyloxymurea-resistant Chinese hamster ovary cells with elevated levels of ribonucleotide reductase activity" J Cell Physiol 106:309-319, 1981.
	Holmlund, "Applying antisense technology: Affinitak and other antisense oligonucleotides in clinical development" Ann N Y Acad Sci 1002:244-51, 2003.
	Huang et al., "Ribonucleotide reductase R2 gene expression and changes in drug sensitivity and genome stability" Cancer Res. 57(21):4876-81, 1997.
	Hurta et al., "Early induction of ribonucleotide reductase gene expression by transforming growth factor beta
EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	1 in malignant H-ras transformed cell lines" J Biol Chem 266(35):24097-24100, 1991.
	Hurta and Wright, "Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent" J Biol Chem 267:7066-7071, 1992.
	Hurta and Wright, "Alterations in the cyclic AMP signal transduction pathway regulating ribonucleotide reductase gene expression in malignant H-ras transformed cell lines." J Cell Physiol 158:187-197, 1994.
	Hurta and Wright, "Malignant transformation by H-ras results in aberrant regulation of ribonucleotide reductase gene expression by transforming growth factor-beta 1" J Cell Biochem 57:543-556, 1995.
	Jelinek et al., "RAS and RAF-1 form a signalling complex with MEK-1 but not MEK-2" Mol Cell Biol 14:8212-8218, 1994.
	Jensen et al., "Identification of genes expressed in premalignant breast disease by microscopy-directed cloning" Proc Nat Acad Sci USA 91:9257-9261, 1994.
	Kohn, "Regulatory genes and drug sensitivity" J Natl Cancer Inst 88(18):1255-6, 1996.
	Koong et al., "Hypoxic activation of nuclear factor-kappa B is mediated by a Ras and Raf signaling pathway and does not involve MAP kinase (ERK1 or ERK2)" Cancer Res 54(20):5273-9, 1994.
	Kuschak et al., "c-Myc initiates illegitimate replication of the ribonucleotide reductase R2 gene" Oncogene 21:909-920, 2002.
	Leevers et al., "Requirement for Ras in Raf activation is overcome by targeting Raf to the plasma membrane" Nature 369(6479):411-4, 1994.
	Lefebvre-d'Hellencourt et al., "Immunomodulation by cytokine antisense oligonucleotides" Eur Cytokine Netw 6(1):7-19, 1995.
	Lenormand et al., "Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway" J Biol Chem 271(26):15762-8, 1996.
	Lewis et al., "Ribonucleotide reductase from wild type and hydroxyurea-resistant chinese hamster ovary cells" J Cell Physiol 97(1):87-97, 1978.
	Lewis et al., "Assay of ribonucleotide reduction in nucleotide-permeable hamster cells" J Cell Physiol 94(3):287-98, 1978.
	Mann et al., "Ribonucleotide reductase M2 subunit in cellular proliferation, quiescence, and differentiation" J Cancer Res 48:5151-5156, 1988.
	McClarty et al., "Elevated expression of M1 and M2 components and drug-induced posttranscriptional modulation of ribonucleotide reductase in a hydroxyurea-resistant mouse cell line" Biochemistry, 26: 8004-8011, 1987.

EXAMINER	/Dana Shin/	DATE CONSIDERED	10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	McClarty et al., "Molecular mechanisms responsible for the drug-induced posttranscriptional modulation of ribonucleotide reductase levels in a hydroxyurea-resistant mouse L cell line" Biochemistry, 27:7524-7531, 1988.
	McClarty et al., "Increased ferritin gene expression is associated with increased ribonucleotide reductase gene expression and the establishment of hydroxyurea resistance in mammalian cells" J Biol Chem 265:7539-7547, 1990.
	Morgan and Kastan, "p53 and ATM: cell cycle, cell death, and cancer" Adv. Cancer Res., 71:1-25, 1997.
	Motzer et al., "p53 and ATM: cell cycle, cell death, and cancer" J Clin Oncology 20(1):289-296, 2002.
	Negrier et al., "Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie" Ann Oncol 13(9):1460-8, 2002.
	Negrier et al., "Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Français d'Immunothérapie, Fédération Nationale des Centres de Lutte Contre le Cancer" J Clin Oncol 15;18(24):4009-4015, 2000.
	Parker et al., "Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie" Nucleic Acids Research, 19(13):3741, 1991.
	Pavlick et al., "Novel therapeutic agents under investigation for malignant melanoma" Exp Opin Inves Drugs 12:1545-1558, 2003.
	Piepmeyer et al., "In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor" Cancer Res 56(2):359-361, 1996.
	Potsch et al., "p-Alkoxyphenols, a new class of inhibitors of mammalian R2 ribonucleotide reductase: possible candidates for antimelanotic drugs" Mol Pharmacol 45(4):792-796, 1994.
	Price et al., "Lineage analysis in the vertebrate nervous system by retrovirus-mediated gene transfer" Proc Natl Acad Sci USA 84:156-160, 1987.
	Pyrhonen et al., "Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer" J Clin Oncol 17(9):2859-67, 1999.
	Qui et al., "An essential role for Rac in Ras transformation" Nature, 374:457-459, 1995.
	Recchia et al., "Interleukin-2 (IL-2) and 13-cis retinoic acid (RA) prolong disease-free and overall survival in recurrent ovarian cancer (ROC)" Proc. 2004 European Society of Medical Oncology Congress, Vienna, Abst. #491P.
	Reichard, "From RNA to DNA, why so many ribonucleotide reductases?" Science 260:1773-1777, 1993.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No. 50120/008001 Serial No. 10/585,772 Applicant Young et al. Filing Date July 12, 2006 Group 1635 IDS Filed October 14, 2009
--	--

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Rojanasakul, "Antisense oligonucleotide therapeutics: drug delivery and targeting" Advanced Drug Delivery Reviews 18:115-131, 1996.
	Rosolen et al., "Antisense inhibition of single copy N-myc expression results in decreased cell growth without reduction of c-myc protein in a neuroepithelioma cell line" Cancer Res 50:6316-6322, 1990.
	Roy et al., "Inhibition of ribonucleotide reductase by nitric oxide derived from thionitrites: reversible modifications of both subunits" Biochemistry 34:5411-5418, 1995.
	Saeki et al., "Immunohistochemical detection of ribonucleotide reductase in human breast tumors" Int. J. Oncol. 6:523-529, 1995.
	Salem et al., "High level expression of the large subunit of mouse ribonucleotide reductase in a baculovirus system" FEBS Lett 323(1-2):93-5, 1993.
	Santarossa et al., "Ribonucleotide reductase inhibition in the treatment of advanced prostate cancer: an experimental approach with hydroxyurea and gallium nitrate in 20 patients" Eur J Cancer 31a(10):1718, 1995.
	Scanlon et al., "Oligonucleotide-mediated modulation of mammalian gene expression" FASEB J 9:1288-1296, 1995.
	Seheult et al., Abstracts of the General Meeting of the American Society for Microbiology, 102:191, 2002.
	Shaw et al., "Modified deoxyoligonucleotides stable to exonuclease degradation in serum" Nucleic Acids Res 19:747-750, 1991.
	Slabaugh et al., "Vaccinia Virus Ribonucleotide Reductase Expression and Isolation of the Recombinant Large Subunit" J Biol Chem 268(24):17803-17810, 1993.
	Standart et al., "Maternal mRNA from clam oocytes can be specifically unmasked in vitro by antisense RNA complementary to the 3'-untranslated region" Genes Dev 4(12A):2157-2168, 1990.
	Stubbe, "Protein radical involvement in biological catalysis?" Ann Rev Biochem 58:257-285, 1989.
	Sun et al., "Gene transfer of antisense hypoxia inducible factor-1 alpha enhances the therapeutic efficacy of cancer immunotherapy" Gene Therapy 8:638-645, 2001.
	Szekeres et al., "Biochemical and antitumor activity of trimidox, a new inhibitor of ribonucleotide reductase" Cancer Chemother Pharmacol 34:63-66, 1994.
	Takeda and Weber, "Role of Ribonucleotide Reductase in Expression of Neoplastic Program" Life Science, 28:1007-1014, 1981.
	Thelander et al., "Ribonucleotide reductase from calf thymus. Separation of the enzyme into two nonidentical subunits, proteins M1 and M2" J Biol Chem 255:7426-7432, 1980.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Thelander et al., "Subunit M2 of mammalian ribonucleotide reductase. Characterization of a homogeneous protein isolated from M2-overproducing mouse cells." J Biol Chem., 260:2737-2741, 1985.
	Thelander and Berg, "Isolation and characterization of expressible cDNA clones encoding the M1 and M2 subunits of mouse ribonucleotide reductase" Mol Cell Biol 6(10):3433-3442, 1986.
	Thelander and Thelander, "Molecular cloning and expression of the functional gene encoding the M2 subunit of mouse ribonucleotide reductase: a new dominant marker gene" EMBO J 8(9):2475-2479, 1989.
	Tonin et al., "Chromosomal assignment of amplified genes in hydroxyurea-resistant hamster cells" Cytogenet Cell Genet 45:102-108, 1987.
	Tourani et al., "Subcutaneous interleukin-2 and interferon alfa administration in patients with metastatic renal cell carcinoma: final results of SCAPP III, a large, multicenter, phase II, nonrandomized study with sequential analysis design--the Subcutaneous Administration Propeukin Program Cooperative Group" J Clin Oncol 21(21):3987-3994, 2003.
	Van Herpen et al., "Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party" Br J Cancer 82(4):772-776, 2000.
	Wagner, "Gene inhibition using antisense oligodeoxynucleotides" Nature 372:333-335, 1994.
	Wagner et al., "Potent and selective inhibition of gene expression by an antisense heptanucleotide" Nature Biotechnology, 14:840-844, 1996.
	Weber, "Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture" Cancer Res 43:3466-3492, 1983.
	Weckbecker et al., "Effects of N-hydroxy-N'-aminoguanidine derivatives on ribonucleotide reductase activity, nucleic acid synthesis, clonogenicity, and cell cycle of L1210 cells" Cancer Res 47(4): 975-978, 1987.
	Wright and Anazodo, "Altered expression of ribonucleotide reductase and role of M2 gene amplification in hydroxyurea-resistant hamster, mouse, rat, and human cell lines" Somat Cell Mol Genet 13:155-165, 1987.
	Wright et al., "Regulation and drug resistance mechanisms of mammalian ribonucleotide reductase, and the significance to DNA synthesis" Biochem Cell Biol 68:1364-1371, 1990.
	Wright et al., "Hydroxyurea and related compounds" Antimetabolite and Cytotoxic Analogs 1:15-27, 1989.
	Wright and Anazodo, "Altered mammalian ribonucleoside diphosphate reductase from mutant cell lines" The Cancer Journal, 8(4):185-189, 1995.
	Wright, "Antisense molecules and their potential for the treatment of cancer and AIDS" Encyl Pharmacol Therapeut 128:89-111, 1989.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/~~

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Yakubov et al., "Mechanism of oligonucleotide uptake by cells: involvement of specific receptors?" Proc Natl Acad Sci USA 86:6454-6458, 1989.
	GenBank Entry NM_001034, "Homo sapiens ribonucleotide reductase M2 polypeptide (RRM2), mRNA." (20-DEC-2003), National Center for Biotechnology Information, Bethesda, MD.
	GenBank Entry NM_009104, "Mus musculus ribonucleotide reductase M2 (Rrm2), mRNA." (20-DEC-2003), National Center for Biotechnology Information, Bethesda, MD.
	GenBank Entry X68127, "M.auratus mRNA for ribonucleotide reductase M2 subunit." (30-JUN-1993), National Center for Biotechnology Information, Bethesda, MD.
	Press Release dated April 14, 1999 – Lorus Therapeutics Signs Agreement to Acquire GeneSense Technologies Inc.
	Press Release dated November 16, 1999 – Lorus Therapeutics Files IND Application Following Positive Preclinical Results of Anti-Cancer Drug GTI 2040.
	Press Release dated November 22, 1999 – Lorus Therapeutics Announces Dramatic Anti-Tumor Results For GTI 2040.
	Press Release dated December 7, 1999 – Lorus Therapeutics Announces FDA Approval To Begin Clinical Trials Of Anti-Cancer Drug GTI 2040.
	Press Release dated December 20, 1999 – Lorus Therapeutics Reports Results Of International Scientific Study.
	Press Release dated January 26, 2000 – Lorus Therapeutics Receives Issued United States Patent For Invention Of Key Anti-Cancer Drugs.
	Press Release dated February 7, 2000 – Lorus Therapeutics' Anti-Cancer Drug NC 381 Inhibits The Spread Of Human Melanoma Tumor Cells in Mice.
	Press Release dated February 28, 2000 – Lorus Therapeutics' Lead Anticancer Drugs Reduce Tumor Growth In Mouse Models With Human Prostate Cancer Cells.
	Press Release dated March 30, 2000 – Findings on Lorus Therapeutics' Lead Anti-Cancer Drug Presented At Annual Meeting Of American Association for Cancer Research.
	Press Release dated May 23, 2000 – Progress in Lorus Therapeutics' GTI-2040 Phase I/II Clinical Trial.
	Press Release dated October 17, 2000 – Lorus Announces Intention To Enter Phase II Clinical Trials For GTI-2040 With Strategic Supply Alliance.
	Press Release dated October 19, 2000 – Lorus Therapeutics Presents Anticancer Drug GTI-2040 at International Oncology Meeting In Greece.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50120/008001
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/585,772
		Applicant	Young et al.
		Filing Date	July 12, 2006
		Group	1635
		IDS Filed	October 14, 2009
(37 C.F.R. § 1.98(b))			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Press Release dated March 5, 2001 – Lorus Therapeutics To Present Research of Lead Antisense Drug at Industry Conference.
	Press Release dated March 26, 2001 – Lorus Therapeutics To Present Three Anti-Cancer Drugs at Annual Meeting Of The American Association For Cancer Research.
	Press Release dated May 2, 2001 – Lorus Therapeutics Inc. Announces Two New Members To Its Board Of Directors.
	Press Release dated May 9, 2001 – Lorus Therapeutics Inc. To Present Clinical Results For Lead Antisense AntiCancer Drug at ASCO.
	Press Release dated July 18, 2001 – Lorus Therapeutics Reports Year-End Results.
	Press Release dated July 20, 2001 – Lorus Therapeutics Reports Year-End Results.
	Press Release dated July 24, 2001 – Lorus Therapeutics' GTI-2040 Prolongs Survival Rate In Mice Models With Lymphoma In Pre-Clinical Testing.
	Press Release dated October 17, 2001 – Lorus Therapeutics Reports First Quarter Results.
	Press Release dated October 30, 2001 – Lorus Advances Antisense Clinical Program For Renal Cell Carcinoma.
	Press Release dated February 21, 2002 – Scientific Publication Describes Oncogene Interaction With Lorus Anticancer Target.
	Press Release dated June 18, 2002 – Lorus Therapeutics And U.S. National Cancer Institute To Collaborate On The Conduct Of Multiple Phase II Clinical Trials With Lorus' GTI-2040.
	Press Release dated October 15, 2002 – Lorus Therapeutics Reports First Quarter Results.
	Press Release dated January 17, 2003 – Lorus Therapeutics Reports Second Quarter Results.
	Press Release dated February 5, 2003 – Lorus Announces Expansion of Renal Cell Carcinoma Clinical Trial To Major Oncology Centers In The United States.
	Press Release dated March 10, 2003 – Lorus Therapeutics Allowed United States Patent to Protect Key Antisense Anticancer Target.
	The Ottawa Citizen, June 19, 2002 – "Lorus Therapeutics shares jump after new trials approved."
	Copy of Office Action, mailed November 13, 2007, for U.S. Patent Application No. 10/545,152.
	Copy of Office Action, mailed May 15, 2008, for U.S. Patent Application No. 10/545,152.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DS/

SUBSTITUTE FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) PATENT AND TRADEMARK OFFICE  INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)  (37 C.F.R. § 1.98(b))	Attorney Docket No. 50120/008001 Serial No. 10/585,772 Applicant Young et al. Filing Date July 12, 2006 Group 1635 IDS Filed October 14, 2009
--	--

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION	
	Copy of Office Action, mailed February 20, 2009, for U.S. Patent Application No. 10/545,152.
	Copy of Office Action, mailed October 14, 1999, for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed July 6, 2000, for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed March 27, 2001, for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed June 5, 2002, for U.S. Patent Application No. 9/249,247.
	Copy of Notice of Allowance, mailed January 14, 2003 for U.S. Patent Application No. 9/249,247.
	Copy of Office Action, mailed March 28, 2006, for U.S. Patent No. 10/447,136.
	Copy of Office Action, mailed September 11, 2006, for U.S. Patent No. 10/447,136.
	Copy of Office Action, mailed January 5, 2007, for U.S. Patent No. 10/447,136.
	Copy of Office Action, mailed July 9, 2007, for U.S. Patent No. 10/447,136.
	Copy of Notice of Allowance, mailed February 6, 2008, for U.S. Patent No. 10/447,136.

EXAMINER /Dana Shin/	DATE CONSIDERED 10/28/2009
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

~~ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.~~ /DS/